Monte Rosa Therapeutics (GLUE) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, gaining 55.8% versus a gain of 33.9%. Over five years, GLUE leads with a -51.3% price change compared with -97.1% for JBIO. Jade Biosciences is the larger company by market cap ($899.9 million vs $880.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | JBIO |
|---|---|---|
| Share price | $10.32 | $14.15 |
| Market cap | $880.43M | $899.90M |
| 1-day change | +1.47% | +2.76% |
| YTD return | -34.18% | -8.30% |
| 1-year return | +33.85% | +55.84% |
| 5-year return | -51.32% | -97.14% |
| EPS (TTM) | $-1.75 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $28.00 |
| 52-week low | $7.65 | $8.36 |
| Distance from 52-week high | -59.95% | -49.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +171.32% | +254.28% |
| Average volume | 1.31M | 888.66K |
| Shares outstanding | 85.31M | 63.60M |
| Employees | 173 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed GLUE by 22.0 percentage points over the past year.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
GLUE vs JBIO FAQ
Which is bigger, Monte Rosa Therapeutics or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $899.90M compared with $880.43M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, GLUE or JBIO?
JBIO returned +55.84% over the past 12 months, compared with +33.85% for GLUE (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and Jade Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Monte Rosa Therapeutics and Biotechnology: Pharmaceutical Preparations for Jade Biosciences.